[an error occurred while processing this directive]|[an error occurred while processing this directive]
乳腺癌脑转移全脑放疗预后及预后指数分析
章倩,陈剑,俞晓立,蔡钢,杨昭志,曹璐,陈星星,郭小毛,陈佳艺
200032 上海,复旦大学上海医学院肿瘤学系复旦大学附属肿瘤医院放疗科
Analysis of prognostic factors and prognostic indices in breast cancer patients with brain metastases after whole-brain radiotherapy
ZHANG Qian, CHEN Jian, YU Xiao-li, CAI Gang, YANG Zhao-zhi, CAO Lu, CHEN Xing-xing, GUO Xiao-mao, CHEN Jia-yi.
Department of Radiation Oncology, Cancer Hospital of Fudan University;Department of Oncology, Shanghai Medical College of Fudan University;Shanghai 200032,China Corresponding author:CHEN Jia-yi
Objective To analyse the prognostic factors and 5 prognostic indices in breast cancer patients with brain metastases after whole-brain radiotherapy (WBRT). Methods Log-rank test (for univariate prognostic analysis) and Cox regression analysis (for multivariate prognostic analysis) were performed in 99 breast cancer patients with BM who received WBRT from January 2006 to February 2010. The sensitivities and specificities of prognostic indices, including recursive partitioning analysis (RPA), graded prognostic assessment (GPA), basic score for brain metastases (BSBM), Rades, and Carsten, were calculated and compared. Results The median follow-up was 49 months;the median survival was 10 months. The univariate analysis showed that age, Karnofsky performance score (KPS) at the diagnosis of BM, presence of extracranial metastases, primary tumor control, number of BM, and systemic treatment after WBRT were significantly correlated with overall survival (χ2=0.00—55.51, P=0.000—0.013). The multivariate analysis showed that KPS of<70 and systemic treatment after WBRT were significantly correlated with overall survival (χ2=35.26, P=0.000;χ2=7.21, P=0.007). In predicting ≤3 months of survival for breast cancer patients with BM, the sensitivities and specificities of RPA, GPA, BSBM, Rades, and Carsten were 100% and 85%, 95% and 62%, 95% and 86%, 95% and 84%, and 95% and 85%, respectively. Conclusions Systemic treatment after WBRT can improve overall survival in breast cancer patients with BM. In predicting ≤3 months of survival, RPA is the most sensitive index, and BSBM is the most specific index.
ZHANG Qian,CHEN Jian,YU Xiao-li et al. Analysis of prognostic factors and prognostic indices in breast cancer patients with brain metastases after whole-brain radiotherapy[J]. Chinese Journal of Radiation Oncology, 2013, 22(3): 186-189.
[1] Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trial. Int J Radiat Oncol Biol Phys,1997,37:745-751. [2] Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases:a multiinstitutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys,2010,77:655-661. [3] Lorenzoni J, Devriendt D, Massager N, et al. Radiosurgery for treatment of brain metastases:estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys,2004,60:218-224. [4] Carsten N, Kirsten M, Sabrina TA, et al. Prognostic scores in brain metastases from breast cancer. BMC Cancer,2009,9:105. [5] Rades D, Dunst J, Schild SE. A new scoring system to predicting the survival of patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol,2008,184:251-255. [6] Niwinska A, Murawska M, Pogoda K. Breast cancer brain metastases:differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol,2010,21:942-948. [7] Kim HJ, Im SA, Keam B, et al. Clinical outcome of central nervous system metastases from breast cancer:differences in survival depending on systemic treatment. J Neurooncol,2012,106:303-313. [8] Chargari C, Kirova YM, Dieas V, et al. Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. J Neurooncol,2009,93:379-384. [9] Park IH, Ro J, Lee KS, et al. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol,2009,20:56-62. [10] Lin NU, Carey LA, Liu MC, et al. Phass Ⅱ trial of lapatinib for brain betastases in patients with human epidermal growth receptor 2-positive breast cancer. J Clin Oncol,2008,26:1993-1999. [11] 周麟,刘佳,卢铀.放疗在脑转移性肿瘤中的应用及其进展.中华放射肿瘤学杂志,2008,17:321-325. [12] Andrews DW, Scott CB, Sperduto PW, el al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with on to three brain metastases:phase Ⅲ results of the RTOG 9508 randomised trial. Lancet,2004,363:1665-1672. [13] Carsten N, Minesh PM. Prognostic indices for brain metastases-usefulness and challenges. Radiat Oncol,2009,4:10. [14] Nam BH, Kim SY, Han HS, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res,2008,10:20. [15] Park BB, Uhm JE, Cho EY, et al. Prognostic factor analysis in patients with brain metastases from breast cancer:how can we improve the treatment outcomes ?Cancer Chemother Pharmacol,2009,63:627-633. [16] Harputluoglu H, Dizdar O, Aksoy S, et al. Characteristics of breast cancer patients with central nervous system metastases:a single-center experience. J Natl Med Assoc,2008,100:521-526. [17] Lee SS, Ahn JH, Kim MK, et al. Brain metastases in breast cancer:prognostic factors and management. Breast Cancer Res Treat,2007,111:523-530. [18] Gaspar LE, Mehta MP, Patchell RA, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases:a systematic review and evidence-based clinical practice guideline. J Neurooncol,2010,96:17-32.